These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 22366187)

  • 1. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
    Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
    Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?
    Pasoglou V; Larbi A; Collette L; Annet L; Jamar F; Machiels JP; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
    Prostate; 2014 May; 74(5):469-77. PubMed ID: 24375774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
    Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.
    Lecouvet FE; Geukens D; Stainier A; Jamar F; Jamart J; d'Othée BJ; Therasse P; Vande Berg B; Tombal B
    J Clin Oncol; 2007 Aug; 25(22):3281-7. PubMed ID: 17664475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance of
    Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
    Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
    J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostate cancer - detection of metastases: MRI or scintigraphy better?].
    Schilling D
    Aktuelle Urol; 2013 May; 44(3):173-4. PubMed ID: 23712268
    [No Abstract]   [Full Text] [Related]  

  • 8. Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study.
    Jouvet JC; Thomas L; Thomson V; Yanes M; Journe C; Morelec I; Bracoud L; Durupt F; Giammarile F; Berthezene Y
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):176-85. PubMed ID: 23331931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
    Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
    Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and (99m)Tc-MDP whole-body bone scanning for imaging osteolytic bone metastases.
    Zhang L; Chen L; Xie Q; Zhang Y; Cheng L; Li H; Wang J
    BMC Med Imaging; 2015 Mar; 15():7. PubMed ID: 25885599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body magnetic resonance imaging and prostate cancer metastases: a new gold standard of detection, but does it help us and at what cost?
    Linton KD; Catto JW
    Eur Urol; 2012 Jul; 62(1):76-7. PubMed ID: 22424664
    [No Abstract]   [Full Text] [Related]  

  • 14. Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer.
    Fang AM; Chapin BF; Shi CW; Sun J; Qayyum A; Kundra V; Corn PG; Kuban DA; Ravizzini GC; Surasi DSS; Ma J; Bathala TK
    Prostate Cancer Prostatic Dis; 2024 Sep; ():. PubMed ID: 39289537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
    Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
    Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic value of whole-body MRI and bone scintigraphy in the detection of osseous metastases in patients with breast cancer--A Prospective Double-Blinded Study at two Hospital Centers].
    Ohlmann-Knafo S; Kirschbaum M; Fenzl G; Pickuth D
    Rofo; 2009 Mar; 181(3):255-63. PubMed ID: 19229791
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
    World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
    J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
    Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
    AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.